The PlexusDx Precision Peptide Genetic Test identifies variants in GIPR and FTO, and MC4R genes that influence individual response to GLP-1 therapy
Well continue exploring these concerns in the following sections
In related studies, Michael Nauck observed in 1986 that the incretin effect was lost or severely reduced in people with type 2 diabetes [10], making it unlikely that incretins would be useful therapeutically
Patients exploring currently available, provider-prescribed options such as Mounjaro or Zepbound may recognize a similar philosophy, since these treatments are also adjusted gradually under supervision rather than started at a high level immediately
Some report losing 15 to 20 pounds over six months without dramatically changing their habits, because the medication made it easier to stop eating at a reasonable point
Conlan B, Stoll T, Gorman JJ, Saur I, Rathjen JP